For the Jones Industrial Average to make its 2018 targets, Pfizer and Merck will to have to do their part to help. But they both lagged the markets in 2017.
Here is a consensus forecast of each of the 30 Dow Jones Industrial stocks, including a forward 12-month consensus analyst price target and an expected 2018 total return on each.
In a year that saw the Dow add more than 24%, 5 stocks posted share price declines ranging from 1% to 45%. How did that happen?
UnitedHealth, American Express, Merck, and IBM led the DJIA to a positive finish on Thursday.
The December 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
One strategy that has been popular each year as investors rebalance and make changes is the so-called Dogs of the Dow.
With the passage of tax reform looking almost certain, and with companies continuing to prove that all-time highs in the market will not hurt spending cash on share buybacks, the continuation of…
Caterpillar, UnitedHealth, Merck, and Verizon were among the largest losers among DJIA stocks on Thursday.
The November 30 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
Apple, Disney, Merck, and Pfizer were the leading gainers among the Dow 30 stocks on Monday. Bitcoin settled up 23% after its first trading session.
The question for investors is pretty simple: 2017 was great, but what do they do for an encore in 2018?
Some down and out stocks don't always stay down, and sometimes great turnarounds and recoveries can create huge victories for opportunistic and visionary investors.
Microsoft and Vise were Wednesday's big DJIA gainers while Merck and Disney dipped the most.
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
One area to look at in this overbought and pricey market is pharmaceuticals. These five now are considered to be “deep value” plays at Merrill Lynch.
